Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 17/20 | 0.57 |
| ▸ | GSK3B | P49841 | 15/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
| ▸ | KLK1 | P06870 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | WNT1 | P04628 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201451 | 0.81 | ROCK2 (0.54) | DYRK1AGSK3BROCK2WNT1 | |
| SCHEMBL27201264 | 0.80 | GSK3B (0.56) | DYRK1AGSK3B | |
| SCHEMBL27201421 | 0.79 | DYRK1A (0.50) | DYRK1AGSK3BWNT1 | |
| SCHEMBL27201655 | 0.79 | GSK3B (0.69) | DYRK1AGSK3B | |
| SCHEMBL27201405 | 0.78 | DYRK1A (0.67) | DYRK1AGSK3BWNT1 | |
| SCHEMBL30885311 | 0.76 | DYRK1A (0.59) | DYRK1AGSK3B | |
| SCHEMBL27201475 | 0.76 | DYRK1A (0.71) | DYRK1AWNT1 | |
| SCHEMBL27201483 | 0.76 | DYRK1A (0.59) | DYRK1AGSK3B | |
| SCHEMBL27201479 | 0.75 | DYRK1A (0.48) | DYRK1AGSK3BWNT1 | |
| SCHEMBL21292273 | 0.73 | DYRK1A (1.00) | DYRK1AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | DYRK1A 2404/4885GSK3B 95/4885KLKB1 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.